Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634110 · ClinicalTrials.gov registry record · Phase 2
Brigatinib Before Brain Irradiation Trial (B3i Trial)
A Phase 2 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04634110 is a Phase 2 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 1 participants.
The verdict
NCT04634110, a Phase 2 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a single arm phase II study of brigatinib alone for patients with brain metastases from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), who have either not been treated previously with a tyrosine kinase inhibitor (TKI) targeting ALK or who have had prior exposure to crizotinib.
Interventions
- DRUG Brigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634110
The ClinicalTrials.gov registry entry for NCT04634110 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brigatinib is the first listed.
NCT04634110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04634110 about?
NCT04634110 is a clinical study titled "Brigatinib Before Brain Irradiation Trial (B3i Trial)". This is a single arm phase II study of brigatinib alone for patients with brain metastases from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), who have either not been treated previously with a tyrosine kinase inhibitor (TKI) targeting ALK or who have had prior exposur...
What is the current status of trial NCT04634110?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-11-17. Estimated completion is 2022-04-14.
What interventions are being tested in trial NCT04634110?
The interventions under investigation include: Brigatinib (DRUG).
Who is sponsoring clinical trial NCT04634110?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.